High-density lipoprotein and cardiac glucose metabolism: Implications for management of acute coronary syndromes

Abstract

Get full access to this article

View all access options for this article.

References

Drew

Rye

Duffy

et al.

The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012; 8: 237–245.

Heywood

Richart

Henstridge

et al.

High-density lipoprotein delivered after myocardial infarction increases cardiac glucose uptake and function in mice. Sci Transl Med 2017; 9: 1–10.

Johnston

Lewandowski

. Fatty acid metabolism and contractile function in the reperfused myocardium. Multinuclear NMR studies of isolated rabbit hearts. Circ Res 1991; 68: 714–725.

Zhao

Weng

Chen

et al.

Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: A contemporary meta-analysis of randomised controlled trials. Heart 2010; 96: 1622–1626.

Selker

Beshansky

Sheehan

et al.

Out-of-hospital administration of intravenous glucose–insulin–potassium in patients with suspected acute coronary syndromes: The IMMEDIATE randomized controlled trial. JAMA 2012; 307: 1925–1933.

Selker

Udelson

Massaro

et al.

One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial). Am J Cardiol 2014; 113: 1599–1605.